[go: up one dir, main page]

AR086800A1 - Composicion farmaceutica oftalmologica topica que contiene regorafenib - Google Patents

Composicion farmaceutica oftalmologica topica que contiene regorafenib

Info

Publication number
AR086800A1
AR086800A1 ARP120102339A ARP120102339A AR086800A1 AR 086800 A1 AR086800 A1 AR 086800A1 AR P120102339 A ARP120102339 A AR P120102339A AR P120102339 A ARP120102339 A AR P120102339A AR 086800 A1 AR086800 A1 AR 086800A1
Authority
AR
Argentina
Prior art keywords
topica
pharmaceutical composition
composition containing
containing regorafenib
ophthalmological pharmaceutical
Prior art date
Application number
ARP120102339A
Other languages
English (en)
Inventor
Dr Bttger Michael
Dr Degenfeld Georges
Dr Freundlieb Julia
Dr Hirth-Dietrich Claudia
Dr Keldenich Joerg
Dr Klar Jrgen
Dr Muenster Uwe
Dr Ohm Andreas
Dr Richter Annett
Dr Riedl Bernd
Original Assignee
Bayer Ip Gmbh
Bayer Pharma Aktiengesselschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh, Bayer Pharma Aktiengesselschaft filed Critical Bayer Ip Gmbh
Publication of AR086800A1 publication Critical patent/AR086800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas oftalmológicas tópicas que contienen regorafenib, un hidrato, solvato o sal farmacéuticamente aceptable del mismo o un polimorfo del mismo y su procedimiento de preparación y su uso para el tratamiento de trastornos oftalmológicos.
ARP120102339A 2011-06-28 2012-06-28 Composicion farmaceutica oftalmologica topica que contiene regorafenib AR086800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14

Publications (1)

Publication Number Publication Date
AR086800A1 true AR086800A1 (es) 2014-01-22

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102339A AR086800A1 (es) 2011-06-28 2012-06-28 Composicion farmaceutica oftalmologica topica que contiene regorafenib

Country Status (26)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
PH (1) PH12013502691A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797038B1 (en) 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
EP3302379B1 (en) * 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
MXPA04011528A (es) * 2002-05-28 2005-02-14 Altana Pharma Ag Preparacion farmaceutica que se puede aplicar por via topica.
KR101139557B1 (ko) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
PL1885336T3 (pl) 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
PL1968594T3 (pl) 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
CA2633414A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating inflammatory skin. eye and/or ear diseases
EP1962803A1 (en) 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CN101678006A (zh) * 2007-05-11 2010-03-24 参天制药株式会社 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
EP2453748A4 (en) 2009-07-16 2013-01-02 Glaxo Wellcome Mfg Pte Ltd METHOD OF TREATMENT

Also Published As

Publication number Publication date
BR112013033831A2 (pt) 2017-02-14
CU20130168A7 (es) 2014-04-24
WO2013000917A1 (en) 2013-01-03
ZA201400646B (en) 2015-11-25
HK1197176A1 (en) 2015-01-09
KR20140048218A (ko) 2014-04-23
GT201300322A (es) 2014-11-13
JP2014518233A (ja) 2014-07-28
AU2012277905A1 (en) 2014-01-16
CL2013003700A1 (es) 2014-07-18
ECSP13013106A (es) 2014-01-31
DOP2013000314A (es) 2014-04-15
AU2012277905A8 (en) 2014-01-30
AP2013007335A0 (en) 2013-12-31
CU24163B1 (es) 2016-03-31
CO6920289A2 (es) 2014-04-10
JP5998213B2 (ja) 2016-09-28
CR20130693A (es) 2016-05-02
PH12013502691A1 (en) 2017-08-23
US20140296301A1 (en) 2014-10-02
PE20141031A1 (es) 2014-08-21
UY34166A (es) 2013-01-31
EA201400064A1 (ru) 2014-05-30
EP2726059A1 (en) 2014-05-07
MX2013015287A (es) 2014-03-31
TN2013000533A1 (en) 2015-03-30
CN103889399A (zh) 2014-06-25
NZ619229A (en) 2016-04-29
CA2840329A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
NZ705860A (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
BR112012018955A2 (pt) combinação para administração simultânea, separada ou sequencial e ligante sigma ou um sal, isômero, pró-droga ou solvato farmaceuticamente aceitável do mesmo
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
ECSP15026386A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib

Legal Events

Date Code Title Description
FB Suspension of granting procedure